NTRK1 and cancer: In this study, LASSBio-1920 showed greater in vitro antitumor activity than LASSBio-1586 and tyrosine kinase receptor inhibitors (pelitinib and sunitinib) when tested against cancer cell lines HCT-116 and PC-9.